Premium
Management of drooling in disabled patients with scopolamine patches
Author(s) -
Mato Abigail,
Limeres Jacobo,
Tomás Inmaculada,
Muñoz Maria,
Abuín Concepción,
Feijoo Javier F.,
Diz Pedro
Publication year - 2010
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2010.03659.x
Subject(s) - drooling , medicine , placebo , quality of life (healthcare) , crossover study , anesthesia , adverse effect , sialorrhea , otorhinolaryngology , physical therapy , surgery , alternative medicine , nursing , pathology
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Drooling is a common problem in disabled individuals and has significant physical, psychosocial and aesthetic repercussions. Scopolamine has been used to treat drooling in a number of medical specialities, including otorhinolaryngology, neurology and palliative care. This study evaluates the efficacy of this treatment in severely disabled patients. WHAT THIS STUDY ADDS • Transdermal scopolamine can be a therapeutic option to control drooling in unco‐operative patients. It is an effective and safe method, although it requires appropriate patient selection and is not free from adverse effects. AIM To evaluate the efficacy of scopolamine administered transdermally for the treatment of drooling in severely disabled patients. METHODS A prospective, randomized, double‐blind, crossover, placebo‐controlled clinical trial was designed. The study group consisted of 30 handicapped patients with persistent drooling. The exclusion criteria were the specific contra‐indications of scopolamine. Severity of drooling was quantified using a modified Thomas‐Stonell and Greenberg visual scale simplified into three grades: 1 = dry; 2 = mild/moderate; 3 = severe/fulsome. The frequency of drooling was estimated using the number of bibs used each day. The baseline observational phase was followed by the application of a 1.5 mg scopolamine (Scopoderm TTS; Novartis Consumer Healthcare, UK) or placebo patch every 72 h for a fortnight. This was followed by a 1 week washout period and then crossover of assignments for 2 weeks. RESULTS At baseline, 77% of patients showed grade 3 of drooling. The placebo administration showed no significant reduction in drooling. We found a significant drooling reduction ( P < 0.005) in the scopolamine group in the 1 and 2 week controls (69% and 80% respectively ≤ grade 3). The mean number of bibs/day decreased during the scopolamine phase from 6/day at baseline to 3/day at the 2 week control. Four patients (13.3%) dropped out because of scopolamine side effects and minor adverse reactions were observed in three other patients. No blood alterations were found during the study period. CONCLUSION Scopolamine can be useful to control drooling in severely disabled patients although it requires appropriate patient selection and is not free from adverse effects.